By Emily Glazer and Christina Rexrode
Wells Fargo Advisors failed to properly verify identification for nearly 220,000 new customers
The Financial Industry Regulatory Authority said it was fining Wells Fargo & Co.
Pfizer Inc. (NYSE:PFE) announced today top-line results from a
double-blind Phase 3 study evaluating pregabalin controlled-release (CR)
formulation in adult patients with postherpetic neuralgia (pain after
shingles or PHN). The results show that pregabalin CR resulted in a
statistically significant positive effect compared to placebo in the
primary endpoint, time to loss of therapeutic response (LTR) in pain
Sign-up for 2014/12/18 - Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.